Eli Lilly and Company reported second-quarter 2026 earnings on Wednesday that exceeded Wall Street estimates and prompted an increase in its annual revenue forecast.
The results underscore the massive commercial impact of the GLP-1 receptor agonist market, as the company captures significant share in the obesity and diabetes sectors.
Driven by the performance of its blockbuster drugs, Eli Lilly raised its full-year 2026 revenue outlook to a range between $85 billion and $87 billion [1]. This represents a notable increase from the company's previous full-year guidance of $82 billion [1].
The growth is primarily attributed to the success of Mounjaro, used for diabetes, and Zepbound, approved for chronic weight management. Mounjaro generated $9.9 billion in revenue during the second quarter [3]. This figure represents a 91 percent increase compared to the same period last year [3].
Zepbound also contributed significantly to the quarterly totals, bringing in $4.9 billion in revenue [4]. The surge in demand for these two treatments has allowed Eli Lilly to widen its lead over competitors such as Novo Nordisk.
The company continues to scale its operations to meet the high volume of prescriptions for these medications. The financial trajectory suggests that the demand for weight-loss and glucose-regulating therapies remains robust as the company expands its market reach.
“Eli Lilly raised its full-year 2026 revenue outlook to a range between $85 billion and $87 billion.”
The revised revenue outlook indicates that Eli Lilly is successfully scaling its manufacturing and distribution to meet the unprecedented demand for GLP-1 drugs. By beating estimates and raising guidance, the company is signaling that the weight-loss market is not yet saturated and that its competitive position against other pharmaceutical giants is strengthening.
